For example, studies on the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors identified an increased risk of type 2 diabetes, diastolic blood pressure, type 1 diabetes, peptic ulcer disease, and depression45. Here, PCSK9 is linked to peptic ulcer disease.